Researchers from the US and China have discovered a structural variant of carbon called 'penta-graphene' - a very thin sheet of pure carbon that resembles the pentagonal pattern of the tiles which pave the streets of Cairo. [ + ]

Researchers from the US and China have discovered a structural variant of carbon called 'penta-graphene' - a very thin sheet of pure carbon that resembles the pentagonal pattern of the tiles which pave the streets of Cairo. [ + ]

Patrys (ASX:PAB) expects to have to delay a planned trial of PAT-SM6 in multiple myeloma due to issues surrounding the manufacture of materials for the study. [ + ]

Invion (ASX:IVX) has completed recruitment in a trial of INV102 in smoking cessation for chronic bronchitis patients, shortly after announcing positive interim results. [ + ]

"What's in a name?" was essentially the Australian government's response when concerns were first expressed about dropping "Science" from the ministerial portfolio titles back in 2013. [ + ]

Bionomics (ASX:BNO) has commenced a phase Ib trial of BNC210, its anxiety and depression drug candidate, and is laying the groundwork for a phase IIa trial due to begin this quarter. [ + ]

The Institute of Bioengineering and Nanotechnology (IBN) at A*STAR has developed a paper-based disposable device that will allow dengue-specific antibodies to be detected easily from saliva within 20 min. [ + ]

Novogen (ASX:NRT) has completed placements to ensure it regains compliance with Nasdaq listing rules, while CEO Dr Graham Kelly prepares to present at two investor conferences over the next two weeks. [ + ]

Shares in Genetic Technologies (ASX:GTG) more than doubled after the company revealed that up to six new breast centres will stock its BREVAGen breast cancer risk test in Q1, with more contracts on the way. [ + ]

Scientists have announced the release of Aquaria - a publicly available web resource that streamlines and simplifies the process of gleaning insight from 3D protein structures. [ + ]

Alchemia (ASX:ACL) plans to explore sales or partnership opportunities for its core assets fondaparinux, its HyACT oncology platform and its VAST drug discovery platform. [ + ]

While genetically modified organisms (GMOs) have imparted many benefits on society, they also have the potential to upset natural ecosystems if they were to escape. Physical containment of GMOs is not foolproof, so attention has since turned to biocontainment. [ + ]

Sirtex Medical (ASX:SRX) has secured a $50,000 Research Connections grant for a project to adapt its SIR-Spheres technology to treat brain cancer and other diseases. [ + ]

A team of scientists has sequenced the genomes of 48 bird species, creating the most detailed tree of life for birds to date. [ + ]

GSK has commenced a phase I trial of antibody technology licensed from Prima BioMed's newly acquired Immutep subsidiary, triggering a seven-figure milestone payment. [ + ]